Price to book forward of The Cooper Companies, Inc. – NASDAQ:COO
This article provides the "Price to book forward" value for The Cooper Companies, Inc. (NASDAQ: COO). The content focuses specifically on this financial metric, indicating a market closed status with no recent trades. It is presented within a financial data platform interface.
Enterprise value to EBIT forward of The Cooper Companies, Inc. – NASDAQ:COO
The article presents the "Enterprise value to EBIT forward" for The Cooper Companies, Inc. (NASDAQ: COO). It is published on TradingView, a financial platform offering various market data and charting tools. The content implicitly indicates data availability for this financial metric for the mentioned company.
Enterprise value to EBITDA forward of The Cooper Companies, Inc. – NASDAQ:COO
The article provides financial information for The Cooper Companies, Inc. (NASDAQ: COO), specifically focusing on its enterprise value to forward EBITDA. It appears to be a stub or a data point from a larger financial analysis platform, likely TradingView, indicating the value and change over a period.
Price to earnings forward of Cooper Companies, Inc. – BMV:COO
This article provides the "Price to earnings forward" value for Cooper Companies, Inc. (BMV:COO). The data is presented simply with a period, value, change, and change percentage, explicitly stating it was "Made by humans." The page layout indicates it is a financial data point from TradingView, focusing specifically on the company's forward P/E ratio.
CooperCompanies strategic pivot to eye care, shares backed by Stifel
CooperCompanies is shifting its strategic focus to concentrate on its contact lens business by divesting its CooperSurgical unit. Stifel has reiterated a Buy rating and an $85 price target for the company's shares, anticipating clearer margins and capital allocation post-divestment. The company's CooperVision segment, which manufactures soft contact lenses, is expected to be the core business moving forward.
Stifel Backs Cooper Companies (COO) as CooperSurgical Sale Talks Progress
Stifel reiterated its Buy rating on Cooper Companies (COO) with a price target of $85, as the company progresses with talks to sell its CooperSurgical unit. The brokerage believes the sale, which would narrow Cooper's focus to its contact lens business, could boost the stock's value to $80 per share, indicating a 21% upside. Proceeds from the sale are expected to fund share repurchases.
Stifel Backs Cooper Companies (COO) as CooperSurgical Sale Talks Progress
Stifel has reiterated a Buy rating on Cooper Companies (COO) with a price target of $85, following news that Cooper is progressing with talks to sell its CooperSurgical unit. The brokerage believes that the settlement of legal issues related to the unit signals an advancement in sale discussions. If the sale proceeds, Cooper would focus on its contact lens business, CooperVision, with Stifel estimating the stock could reach $80 per share, and the CEO plans to use proceeds for share repurchases.
Stifel Backs Cooper Companies (COO) as CooperSurgical Sale Talks Progress
Stifel has reiterated a Buy rating on Cooper Companies (COO) with a price target of $85, anticipating a 17% rise in the stock. This follows the progress in discussions for selling Cooper's surgical business unit, CooperSurgical, which is expected to allow Cooper to focus solely on its contact lens business. The CEO plans to use the majority of sale proceeds for share repurchases.
Biofinity toric from CooperCompanies - monthly lenses that target astigmatism comfort
The Biofinity toric monthly silicone hydrogel lenses from CooperCompanies are designed for individuals with astigmatism, offering comfort and stable vision for extended wear. The lenses use Aquaform material for high oxygen permeability and natural wettability, reducing dryness. Widely available, they cover a broad range of prescriptions and are positioned as a mid-range monthly option.
CooperCompanies gains analyst support, shares hold near recent highs
CooperCompanies (COO) continues to attract positive analyst sentiment, with Barclays and other firms maintaining a "Buy" consensus and a price target around $81. The stock is currently trading near $70.16 on Nasdaq, with a market capitalization of $13.82 billion. The company, which operates in the health-care equipment and supplies segment through CooperVision (contact lenses) and CooperSurgical (women's health), remains focused on earnings releases and analyst revisions.
5 Best Stocks to Buy According to Billionaire Barry Rosenstein
Billionaire Barry Rosenstein's investment picks, as highlighted by Insider Monkey, include Cooper Companies Inc (NASDAQ:COO). The company is favored by 49 hedge funds, with analysts projecting a 17% upside. Stifel reiterated a Buy rating and a price target of $85, driven by Cooper's advancing discussions to sell its CooperSurgical unit, which is expected to allow the company to focus on its contact lens business and potentially fund share repurchases.
5 Best Stocks to Buy According to Billionaire Barry Rosenstein
The article highlights Cooper Companies Inc (NASDAQ:COO) as one of the top stock picks by billionaire Barry Rosenstein. Analysts expect the stock to rise by at least 17% in the next year, with Stifel reiterating a Buy rating and a price target of $85. Cooper is considering selling its CooperSurgical business unit to focus on contact lenses, a move that could further increase the stock's value and lead to share repurchases.
WST Stock Price and Chart — NYSE:WST
This page provides an overview of West Pharmaceutical Services, Inc. (WST) stock, including its current price, performance metrics, key financial stats, and company information. It also includes various trading ideas and technical analyses from the TradingView community, along with analyst ratings and ETF holdings.
CooperCompanies Stock - Analyst consensus and earnings outlook
This article provides an outlook on CooperCompanies (COO) stock, analyzing analyst consensus and earnings expectations. It highlights the company's dual focus on contact lenses (CooperVision) and fertility/women's health (CooperSurgical), noting expectations for continued growth and gradual margin improvement. The report also touches on valuation, the anticipated timing of the next earnings release, and factors influencing investor sentiment.
The Cooper Companies, Inc. (COO) Stock Analysis: Unveiling A Potential 22% Upside
The Cooper Companies, Inc. (COO) is a healthcare sector company specializing in vision care and women's health. Despite recent lackluster stock performance, analysts anticipate a potential 22% upside, with an average target price of $80.57. The company's robust revenue growth, substantial free cash flow, and positive analyst sentiment suggest a compelling opportunity for investors interested in the healthcare space, even though it does not currently offer a dividend.
Did Cooper Companies' Q1 Beat Mask Underlying Weakness
Cooper Companies (COO) reported an adjusted EPS beat in Q1 2026, but concerns arose due to a revenue miss and weak organic growth, particularly in its CooperVision segment. The company faces persistent tariff pressures and broader healthcare inflation, yet managed to improve operating margins through cost discipline. While CooperSurgical showed signs of recovery, the premium valuation of COO suggests high expectations for future growth, necessitating consistent execution and innovation.
The Cooper Companies Stock - Analyst consensus ahead of next earnings
The Cooper Companies (COO) is trading quietly ahead of its next quarterly report, with Wall Street analysts giving a mix of Buy and Hold ratings and a consensus target price above its mid-$60s trading band, indicating it is reasonably valued. The company primarily generates revenue from CooperVision (contact lenses) and CooperSurgical (fertility and women's health products). Its next earnings report is expected in about 75 days, with the market focusing on organic revenue growth and commentary on integration, cost inflation, and pricing power.
Cooper Companies Inc (COO) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Cooper Companies Inc (COO), listing its major shareholders and institutional holdings. Key shareholders include Vanguard Capital Management, BlackRock, and Capital World Investors, with various investment advisor types dominating the ownership. The report also provides a historical overview of institutional shareholding data and related ETF holdings.
Cooper Companies Inc (COO) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of Cooper Companies Inc's (COO) dividends and stock splits. It details cash dividend payouts from 2020 through 2023, consistently at USD 0.03 per share, and also notes a 1-to-4 stock split on December 7, 2023. The company has distributed a total of $9.00 million USD in dividends over the past five years.
Cooper Companies Inc (COO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Cooper Companies Inc (COO) by business segment and geographical region, based on data updated on April 6. The report shows that "Toric and multifocal" and "Sphere, other" are the largest business segments, while the United States and Europe contribute the most to the company's regional revenue. The data is presented for various fiscal years and quarters, with specific figures for FY2026Q1.
Cooper Companies Inc (COO) Earnings Forecast: Future EPS & Revenue Growth Estimates
Cooper Companies Inc (COO) has an earnings forecast score of 7.43, ranking 140th in the Healthcare Equipment & Supplies industry, based on updated data from June 16, 2026. The average analyst price target for COO is $93.00, with a high of $100.00 and a low of $71.00, suggesting a significant upside potential of 20.90%. Twenty analysts generally recommend a "Buy" for COO stock, and the company is expected to report revenues of $1.10 billion and an EPS of $1.12 for the next quarter.
Stifel Adjusts Price Target on Cooper Companies to $85 From $95, Maintains Buy Rating
Stifel has adjusted its price target for Cooper Companies (NYSE:COO) to $85 from $95, while reiterating a Buy rating on the stock. This revision comes after the company's recent financial disclosures. Investors will be monitoring Cooper Companies' performance closely.
The Cooper Companies, Inc. Stock 12‑Month Price Target Cut to $78.77, Implies 17% Upside
The average 12-month price target for The Cooper Companies, Inc. (COO) stock has been lowered to $78.77 from $79.21 by 13 analysts, with a range of $66 to $92. This updated target suggests a potential upside of approximately 17% from its June 16 closing price. The consensus analyst rating for COO remains "Buy" based on opinions from 18 analysts.
Fresenius Medical Care Stock (DE0005785802): Quarterly earnings keep NYSE-listed shares in focus
Fresenius Medical Care's latest quarterly earnings highlight its continued profitability recovery, cost discipline, and exposure to the U.S. market. The company is actively optimizing its operations, product portfolio, and debt position to ensure sustainable growth, while navigating complex regulatory and economic environments. Investors are closely monitoring its performance, especially in relation to its NYSE-listed American depositary shares (FMS).
Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?
The Cooper Companies (COO) is a big-cap stock in the medical instruments and supplies industry, with a market cap of $13.2 billion. Despite a recent 8.6% surge following strong Q2 2026 earnings, COO has underperformed the State Street Healthcare Select Sector SPDR ETF (XLV) over the past three months and the last 52 weeks. Analysts, however, hold a "Moderate Buy" consensus rating with a potential 20.4% upside from current levels.
Building a Global Feedback Engine: The CooperVision Story
CooperVision partnered with Atrium to transform its Voice of the Customer program by shifting from lengthy, low-response surveys to a Salesforce-based "quick-survey" model. This collaboration led to a significant increase in response rates, up to 10% during the pilot phase in regions like DACH and France, and established a scalable foundation for global feedback. The success is attributed to a unified vision, collaborative workshops, and an integrated "one-team" approach between CooperVision and Atrium.
Cooper Companies (COO) Stock After DCF Discount And High P/E Ratio
This article analyzes Cooper Companies (COO) stock using discounted cash flow (DCF) and P/E ratio methods. While DCF suggests the stock is undervalued, the P/E ratio indicates it is currently overvalued compared to industry averages. The article presents bull and bear case narratives, highlighting different assumptions about future growth and margins to help investors decide which outlook aligns with their expectations for the stock.
Cooper Companies (NasdaqGS:COO) Stock Forecast & Analyst Predictions
This article provides a stock forecast and analyst predictions for Cooper Companies (COO), highlighting its future growth potential with expected earnings growth of 28.8% per year. It details recent earnings guidance updates for fiscal years 2025 and 2026, stock performance, and significant events like the Q2 2026 earnings beat and discussions around the potential sale of CooperSurgical. The report also includes insider transaction details, risk assessments, and analyst perspectives on the company's valuation and strategic direction.
Stifel reiterates Buy on Cooper Companies stock amid sale talks
Stifel reiterated a Buy rating and an $85.00 price target on Cooper Companies (NASDAQ:COO) after the company’s Q2 2026 earnings call, noting management is moving towards selling CooperSurgical. The firm projects an approximately 18% upside from current levels, valuing the pure-play CooperVision business at around $80 per share. This follows strong Q2 results where EPS and revenue exceeded expectations, despite a lowered full-year revenue guidance due to a softer Asia-Pacific outlook and plans to sell Cooper Surgical Inc.
Multiple Catalysts Prompted The London Company Small-Mid Cap Strategy’s Cooper Companies (COO) Addition
The London Company Small-Mid Cap Strategy added Cooper Companies (COO) to its portfolio in Q1 2026, despite a challenging quarter where the fund underperformed the Russell 2500 Index. The strategy cited Cooper Companies' strong market position in contact lenses, potential for margin expansion, and attractive valuation with recent insider buying as key reasons for the addition. However, the article notes that Cooper Companies is not among the most popular hedge fund stocks and suggests that certain AI stocks may offer higher returns.
Stifel reiterates Buy on Cooper Companies stock amid sale talks By Investing.com
Stifel reiterated a Buy rating and an $85.00 price target on Cooper Companies (NASDAQ:COO) after the company announced it is actively discussing the sale of CooperSurgical. The firm believes the recent fertility settlement signals management's intent to sell CooperSurgical, leading to a pure-play CooperVision. Stifel's analysis suggests approximately 18% upside from current levels, with InvestingPro also indicating the stock is undervalued despite trading at a high earnings multiple.
Stifel reiterates Buy on Cooper Companies stock amid sale talks
Stifel has reiterated a "Buy" rating and an $85.00 price target for Cooper Companies (NASDAQ:COO) after the company's second-quarter fiscal 2026 earnings call. The reaffirmation comes amid active discussions for selling CooperSurgical, which would leave Cooper Companies with a pure-play contact lens business under CooperVision. This strategic move and the underlying value of the CooperVision business, along with an InvestingPro analysis indicating the stock is undervalued, support Stifel's positive outlook.
Stifel reiterates Buy on Cooper Companies stock amid sale talks By Investing.com
Stifel reiterated a Buy rating and an $85.00 price target on Cooper Companies (NASDAQ:COO) stock after the company's Q2 fiscal 2026 earnings call. This decision follows Cooper Companies actively pursuing the sale of CooperSurgical and settling a fertility-related case, which analysts believe clears the path for a pure-play CooperVision (contact lens) business. Stifel's analysis suggests an 18% upside from current levels, despite the company lowering its full-year revenue guidance and other firms adjusting price targets due to the planned divestiture.
Heartland Advisors Inc. Invests $15.35 Million in The Cooper Companies, Inc. $COO
Heartland Advisors Inc. has invested $15.35 million in The Cooper Companies (NASDAQ:COO) by purchasing 187,263 shares in the fourth quarter, representing about 0.10% of the medical device maker. This comes as Cooper Companies reported better-than-expected quarterly results and raised its FY2026 guidance. Analyst sentiment is mixed but generally constructive, with a consensus "Hold" rating and an average price target of $82.64.
ING Groep NV Has $223,000 Stake in The Cooper Companies, Inc. $COO
ING Groep NV significantly reduced its stake in The Cooper Companies, Inc. by 89.4% in the fourth quarter, bringing its total holdings to $223,000. Despite several analysts lowering price targets, the consensus remains "Hold" for COO. The company reported solid quarterly earnings, exceeding EPS and revenue estimates, and provided positive FY2026 EPS guidance.
Clorox (NYSE:CLX) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold between $1,001 and $15,000 worth of Clorox (NYSE:CLX) shares on May 15th, as disclosed in a June 8th filing. This sale follows Clorox's recent earnings report where it beat EPS expectations but had revenue in line with estimates, and issued FY 2026 EPS guidance. Despite a consensus "Reduce" rating and some analyst caution, a company director, Pierre R. Breber, bought 5,000 shares in May, indicating mixed insider sentiment.
A Look At Cooper Companies (COO) Valuation After Earnings Beat Litigation Progress And Guidance Reaffirmation
Cooper Companies (COO) recently reported record quarterly revenue and an earnings beat, along with progress in resolving fertility media litigation and reaffirming full-year guidance. This has led to a short-term stock rebound, but its overall year-to-date performance remains weak. Despite trading below some analyst valuation estimates and being considered "undervalued" by one model due to projected free cash flow growth, the company's high P/E ratio compared to industry averages raises concerns about potential upside pressure.
Rep. Gilbert Ray Cisneros, Jr. Buys Conagra Brands (NYSE:CAG) Shares
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently purchased between $1,001 and $15,000 worth of Conagra Brands (NYSE:CAG) stock on May 15th, as disclosed in a June 8th filing. Conagra Brands reported quarterly EPS of $0.39, slightly missing expectations, with revenue of $2.79 billion, a 1.9% year-over-year decrease. Despite a "Reduce" consensus rating from analysts, the company's dividend remains a highlight, offering a 10.7% yield based on the latest $0.35 quarterly payout.
A Look At Cooper Companies (COO) Valuation After Earnings Beat Litigation Progress And Guidance Reaffirmation
Cooper Companies (COO) recently reported record quarterly revenue and an earnings beat, resolved most fertility media litigation, and reaffirmed its full-year guidance. Despite a recent share price rebound, the stock is still down year-to-date and over three years. While some analysts view the stock as undervalued with potential for increased free cash flow and share repurchases, its high P/E ratio compared to peers raises concerns about future upside if growth or margins falter.
Capital World Investors Has $836.66 Million Stock Position in The Cooper Companies, Inc. $COO
Capital World Investors reduced its stake in The Cooper Companies, Inc. by 3.3% in the fourth quarter, yet still holds 10.2 million shares valued at about $836.7 million, equating to a 5.21% ownership. The Cooper Companies delivered strong Q2 results, surpassing EPS and revenue estimates, and resolving claims from a prior fertility media recall. Despite some analysts lowering price targets, the overall sentiment remains constructive, with an average "Hold" rating and a consensus target price of $82.64.
CIBC Asset Management Inc Has $3.83 Million Stock Position in The Cooper Companies, Inc. $COO
CIBC Asset Management Inc significantly increased its stake in The Cooper Companies, Inc. by 69.4% in Q4, now holding 46,763 shares valued at $3.83 million. The Cooper Companies (NASDAQ:COO) recently reported stronger-than-expected Q2 results with EPS of $1.21 and revenue of $1.08 billion, also announcing a resolution to fertility media recall claims. While analysts have mixed views, the company's performance and legal resolution provide a generally constructive outlook.
G-III Apparel (NASDAQ: GIII), ABM Industries (NYSE: ABM), ServiceTitan (NASDAQ: TTAN), And Cooper Companies (NASDAQ: COO) Surge On Strong Earnings Beats
G-III Apparel (GIII), ABM Industries (ABM), ServiceTitan (TTAN), and Cooper Companies (COO) all experienced significant stock surges after reporting stronger-than-expected Q1 or Q2 earnings. G-III Apparel beat revenue estimates, ABM Industries exceeded revenue forecasts, ServiceTitan surpassed adjusted earnings per share estimates, and Cooper Companies beat its adjusted earnings per share outlook. These results highlight a market trend where companies delivering earnings beats are rewarded with sharp share price increases.
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Blink Triple Care Preservative Free U.S. Launch
Bausch + Lomb (BLCO) has launched Blink Triple Care Preservative Free eye drops in the U.S., amidst recent share price cooling despite a strong year. The company's valuation narrative suggests a 60.6% undervaluation with a fair value of $39.23 against a current trading price of $15.46, though this is tempered by governance concerns and a reported net loss. Investors are encouraged to assess the underlying data and risks independently.
The Cooper Companies, Inc. (COO) Stock Analysis: Potential 19.97% Upside and Strong Buy Ratings in Focus
The Cooper Companies, Inc. (COO) shows significant investment potential in the healthcare sector, specializing in contact lenses and women's healthcare. Analysts anticipate a nearly 20% upside with an average target price of $80.79, supported by strong buy ratings and solid financial performance. The company's diversified approach and focus on reinvesting earnings position it as an attractive option for growth-oriented investors in the healthcare industry.
COO Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes COO (Cooper Companies Inc) financials, covering its revenue breakdown, profitability margins, and competitor comparison. Toric and multifocal products are the largest revenue contributors, and the company maintains a gross margin of 63.59%. In the Medical Equipment, Supplies & Distribution industry, COO competes with RVTY and PEN, holding a market capitalization of $13.14B.
Havemeyer Place LP Buys Shares of 29,634 The Cooper Companies, Inc. $COO
Havemeyer Place LP initiated a new stake in The Cooper Companies (NASDAQ:COO) during the fourth quarter, purchasing 29,634 shares valued at approximately $2.43 million. This comes as Cooper Companies reported better-than-expected Q2 earnings, exceeding revenue and EPS estimates, and has resolved most claims related to a prior fertility media recall. Despite some analyst price target reductions, the sentiment surrounding the company remains generally constructive.
Pretax income of Cooper Companies, Inc. – XETR:CP60
This article provides access to the pretax income information for Cooper Companies, Inc. (XETR:CP60) on TradingView. It highlights that market data is provided by ICE Data Services and reference data by FactSet. The content is primarily a gateway to financial data rather than a detailed report.
Book value per share of Cooper Companies, Inc. – XETR:CP60
The article focuses on the book value per share of Cooper Companies, Inc. (XETR:CP60). It presents a financial overview of the company, indicating various financial data points like value, change, and percentage change. The content highlights that the market was closed at the time of publication, and provides copyright and data source information.
Total assets of Cooper Companies, Inc. – XETR:CP60
This article provides financial information for Cooper Companies, Inc. under its XETR:CP60 stock symbol on TradingView. It specifically highlights the total assets of the company. The page also includes various disclaimers regarding market and reference data providers.
Net debt of Cooper Companies, Inc. – XETR:CP60
This article displays a financial overview for Cooper Companies, Inc. (XETR:CP60), focusing specifically on its net debt information. It includes a section on the period value, change, and percentage change. The content appears to be a stub or a placeholder, as no specific financial data is provided beyond the section titles.
